Cognigenics has developed a new RNA-based therapy, COG-201, showing promise in improving memory and reducing anxiety in animals by targeting the serotonin 5-HT2A receptor.
The therapy, administered intranasally, could revolutionize treatment for cognitive impairments and mood disorders.
RNA-Based Therapy in Neuroscience
Scientists at Cognigenics have made a significant advance in the field of neuroscience and mental health treatment. Their groundbreaking research, published in Genomic Psychiatry, demonstrates that a new RNA-based therapy called COG-201 can enhance memory and reduce anxiety in animal models.
COG-201 uses short hairpin RNA (shRNA) to target and reduce the expression of the serotonin 5-HT2A receptor in the brain. This receptor plays a crucial role in regulating mood, anxiety, and cognitive functions. By decreasing its expression, the researchers observed notable improvements in memory and reductions in anxiety-like behaviors in both mice and rats.
Promising Research Outcomes
“Our findings suggest that COG-201 could offer a new approach to treating conditions like mild cognitive impairment and anxiety disorders,” said Dr. Troy T. Rohn, lead author of the study. “What’s particularly exciting is that we’re seeing these effects through a non-invasive, intranasal delivery method.”
The study provides both behavioral and neurophysiological evidence for the efficacy of COG-201. In addition to improved performance on memory tests, treated animals showed changes in neuronal activity that align with enhanced cognitive function. Specifically, the researchers observed decreased spontaneous electrical activity in cortical neurons, suggesting a reduction in overall neural excitability.
Implications for Cognitive and Mood Disorders
This research represents a significant step forward in the development of precision-based therapeutics for neurological and psychiatric disorders. By targeting a specific receptor with RNA interference, COG-201 offers a more precise approach compared to traditional pharmacological treatments.
“We’re particularly encouraged by the potential applications for patients with mild cognitive impairment who also experience anxiety,” noted Dr. Fabio Macciardi, a co-author of the study. “Currently, there’s no single medication that effectively addresses both of these symptoms.”
Future Research Directions
While the results are promising, the researchers caution that further studies, including trials in larger animals and eventually humans, will be necessary to fully understand the therapy’s potential and safety profile.
This innovative approach to treating cognitive and mood disorders could open new avenues for therapeutic interventions. As the global population ages and the prevalence of cognitive impairments increases, therapies like COG-201 may offer hope for millions of people worldwide.
Reference: “Treatment with shRNA to knockdown the 5-HT2A receptor improves memory in vivo and decreases excitability in primary cortical neurons” by Troy T. Rohn, Dean Radin, Tracy Brandmeyer, Peter G. Seidler, Barry J. Linder, Tom Lytle, David Pyrce, John L. Mee and Fabio Macciardi5 August 2024, Genomic Psychiatry.
DOI: 10.61373/gp024r.0043
About Genomic Psychiatry: Genomic Psychiatry (ISSN: 2997-2388) is a peer-reviewed journal published by Genomic Press, New York. It features cutting-edge research in genomics, neuroscience, psychiatry, and related fields, with a focus on innovation and translating scientific discoveries into clinical applications.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.